SlideShare a Scribd company logo
1 of 13
Download to read offline
Using Mobile Phones to Collect
 End Line Evaluation Data for
 the Essential Drug Logistics
    System Pilot in Zambia
        Dr. Arturo Sanabria
        Wendy Nicodemus
Background

• Zambian MoH has invested substantial funds in the
  public sector drug system
   – Health centres continue to have difficulty accessing these
     drugs and medical supplies
• MoH and key partners proposed a pilot project to
  improve drug availability at health centres and
  hospitals across Zambia
Goal of the Pilot
   Test two different logistics system models to select one (or a
 combination/variation) that can be rolled out nationally, in order to
significantly improve the availability of key essential drugs at service
                              delivery sites
The Pilot Models
System A                       System B
  • District Store               • District Store
  remains as                     converted to cross-
  stockholding point             docking point
                         VS
  • Districts submit             • Districts submit
  consolidated orders            individual orders for
  every month and                each facility and
  receive consolidated           receive goods packed
  deliveries from MSL            for individual
                                 facilities
16 Pilot Districts and 8 Control Districts
Essential Drug Logistics System Pilot
Evaluation
• Facilities in pilot and control districts evaluated at
  baseline and endline to determine impact

• Endline evaluation used mobile phones to collect
  data at 259 health facilities and district health offices
  in 16 pilot districts and 8 control districts
Methodology

• Mobile phones used to collect data, including:
   –   Stock status at facility
   –   Storage conditions at facility
   –   Order fulfillment rate
   –   Impact of training in logistics management
• Data from mobile phones sent to EpiSurveyor
  (www.episurveyor.org) for aggregation
• Data shared via the website to all partners involved
Lessons Learned

• Final results presented 5 days after last facility visit
   – Previous evaluations took a month to present final results
• Mobile phone use requires
  detail-oriented data
  management reviewing the
  online database regularly
   – Requires continuous review
     of data
   – Need IT support to address
     any bugs with the mobile
     phones
Lessons Learned
• Preliminary data analysis
  ongoing throughout
  evaluation
• Technology works best
  when mobile phone
  network is strong and can
  be transmitted to server
  immediately
   – When no mobile network,
     data sent to server at a later
     point negating benefit of real-
     time data review
Conclusions
• Mobile phone technology for data collection is
  appropriate when conducting health facility level
  surveys.

• The technology is user-friendly and easy to train.

• This technology is not necessarily the appropriate
  tool for routine site-level data collection as it requires
  a reliable mobile network.
Thank you!
Using Mobile Phones to Collect End Line Evaluation Data for the Essential Drug Logistics System Pilot in Zambia: Dr Arturo Sanabria/Wendy Nicodemus

More Related Content

More from 3GDR

The Future Role of the Doctor
The Future Role of the DoctorThe Future Role of the Doctor
The Future Role of the Doctor3GDR
 
How would the Born Mobile redesign Medicine
How would the Born Mobile redesign MedicineHow would the Born Mobile redesign Medicine
How would the Born Mobile redesign Medicine3GDR
 
Introduction to gdpr
Introduction to gdprIntroduction to gdpr
Introduction to gdpr3GDR
 
Irish HSE EHR strategic business case master briefing deck v1.4
Irish HSE EHR strategic business case master briefing deck v1.4Irish HSE EHR strategic business case master briefing deck v1.4
Irish HSE EHR strategic business case master briefing deck v1.43GDR
 
Alan Connor, eHealth Ireland
Alan Connor, eHealth IrelandAlan Connor, eHealth Ireland
Alan Connor, eHealth Ireland3GDR
 
Can mobiles save lives by Dr Line Kleinebreil (WHO Consultant)
Can mobiles save lives by Dr Line Kleinebreil (WHO Consultant)Can mobiles save lives by Dr Line Kleinebreil (WHO Consultant)
Can mobiles save lives by Dr Line Kleinebreil (WHO Consultant)3GDR
 
Request for Expressions of Interest: The EU mHealth Hub (17 August 2017)
Request for Expressions of Interest: The EU mHealth Hub (17 August 2017)Request for Expressions of Interest: The EU mHealth Hub (17 August 2017)
Request for Expressions of Interest: The EU mHealth Hub (17 August 2017)3GDR
 
Things you need to know about info governance to sell healthtech products int...
Things you need to know about info governance to sell healthtech products int...Things you need to know about info governance to sell healthtech products int...
Things you need to know about info governance to sell healthtech products int...3GDR
 
5G World: Better Networks for Better Healthcare
5G World: Better Networks for Better Healthcare 5G World: Better Networks for Better Healthcare
5G World: Better Networks for Better Healthcare 3GDR
 
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future”...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future”...Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future”...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future”...3GDR
 
Digital Health a call for Government Leadership and cooperation between ICT a...
Digital Health a call for Government Leadership and cooperation between ICT a...Digital Health a call for Government Leadership and cooperation between ICT a...
Digital Health a call for Government Leadership and cooperation between ICT a...3GDR
 
The importance of post-marketing registries for payers and regulators to mana...
The importance of post-marketing registries for payers and regulators to mana...The importance of post-marketing registries for payers and regulators to mana...
The importance of post-marketing registries for payers and regulators to mana...3GDR
 
Deriving more value from real world evidence to ensure timely access of medic...
Deriving more value from real world evidence to ensure timely access of medic...Deriving more value from real world evidence to ensure timely access of medic...
Deriving more value from real world evidence to ensure timely access of medic...3GDR
 
Early evidence development for new products - planning for reimbursement success
Early evidence development for new products - planning for reimbursement successEarly evidence development for new products - planning for reimbursement success
Early evidence development for new products - planning for reimbursement success3GDR
 
Scottish Health Intelligence - creating value for the world
Scottish Health Intelligence - creating value for the worldScottish Health Intelligence - creating value for the world
Scottish Health Intelligence - creating value for the world3GDR
 
Structural market access challenges anti-infectives
Structural market access challenges anti-infectivesStructural market access challenges anti-infectives
Structural market access challenges anti-infectives3GDR
 
Early MA Assessment for Personalized Medicine: a framework to assess the chal...
Early MA Assessment for Personalized Medicine: a framework to assess the chal...Early MA Assessment for Personalized Medicine: a framework to assess the chal...
Early MA Assessment for Personalized Medicine: a framework to assess the chal...3GDR
 
Why OMA... Why Now?
Why OMA... Why Now?Why OMA... Why Now?
Why OMA... Why Now?3GDR
 
Global Pricing and Tender Management: How can i optimise my commercial strate...
Global Pricing and Tender Management: How can i optimise my commercial strate...Global Pricing and Tender Management: How can i optimise my commercial strate...
Global Pricing and Tender Management: How can i optimise my commercial strate...3GDR
 
Pharma Pricing & Market Access
Pharma Pricing & Market AccessPharma Pricing & Market Access
Pharma Pricing & Market Access3GDR
 

More from 3GDR (20)

The Future Role of the Doctor
The Future Role of the DoctorThe Future Role of the Doctor
The Future Role of the Doctor
 
How would the Born Mobile redesign Medicine
How would the Born Mobile redesign MedicineHow would the Born Mobile redesign Medicine
How would the Born Mobile redesign Medicine
 
Introduction to gdpr
Introduction to gdprIntroduction to gdpr
Introduction to gdpr
 
Irish HSE EHR strategic business case master briefing deck v1.4
Irish HSE EHR strategic business case master briefing deck v1.4Irish HSE EHR strategic business case master briefing deck v1.4
Irish HSE EHR strategic business case master briefing deck v1.4
 
Alan Connor, eHealth Ireland
Alan Connor, eHealth IrelandAlan Connor, eHealth Ireland
Alan Connor, eHealth Ireland
 
Can mobiles save lives by Dr Line Kleinebreil (WHO Consultant)
Can mobiles save lives by Dr Line Kleinebreil (WHO Consultant)Can mobiles save lives by Dr Line Kleinebreil (WHO Consultant)
Can mobiles save lives by Dr Line Kleinebreil (WHO Consultant)
 
Request for Expressions of Interest: The EU mHealth Hub (17 August 2017)
Request for Expressions of Interest: The EU mHealth Hub (17 August 2017)Request for Expressions of Interest: The EU mHealth Hub (17 August 2017)
Request for Expressions of Interest: The EU mHealth Hub (17 August 2017)
 
Things you need to know about info governance to sell healthtech products int...
Things you need to know about info governance to sell healthtech products int...Things you need to know about info governance to sell healthtech products int...
Things you need to know about info governance to sell healthtech products int...
 
5G World: Better Networks for Better Healthcare
5G World: Better Networks for Better Healthcare 5G World: Better Networks for Better Healthcare
5G World: Better Networks for Better Healthcare
 
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future”...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future”...Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future”...
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future”...
 
Digital Health a call for Government Leadership and cooperation between ICT a...
Digital Health a call for Government Leadership and cooperation between ICT a...Digital Health a call for Government Leadership and cooperation between ICT a...
Digital Health a call for Government Leadership and cooperation between ICT a...
 
The importance of post-marketing registries for payers and regulators to mana...
The importance of post-marketing registries for payers and regulators to mana...The importance of post-marketing registries for payers and regulators to mana...
The importance of post-marketing registries for payers and regulators to mana...
 
Deriving more value from real world evidence to ensure timely access of medic...
Deriving more value from real world evidence to ensure timely access of medic...Deriving more value from real world evidence to ensure timely access of medic...
Deriving more value from real world evidence to ensure timely access of medic...
 
Early evidence development for new products - planning for reimbursement success
Early evidence development for new products - planning for reimbursement successEarly evidence development for new products - planning for reimbursement success
Early evidence development for new products - planning for reimbursement success
 
Scottish Health Intelligence - creating value for the world
Scottish Health Intelligence - creating value for the worldScottish Health Intelligence - creating value for the world
Scottish Health Intelligence - creating value for the world
 
Structural market access challenges anti-infectives
Structural market access challenges anti-infectivesStructural market access challenges anti-infectives
Structural market access challenges anti-infectives
 
Early MA Assessment for Personalized Medicine: a framework to assess the chal...
Early MA Assessment for Personalized Medicine: a framework to assess the chal...Early MA Assessment for Personalized Medicine: a framework to assess the chal...
Early MA Assessment for Personalized Medicine: a framework to assess the chal...
 
Why OMA... Why Now?
Why OMA... Why Now?Why OMA... Why Now?
Why OMA... Why Now?
 
Global Pricing and Tender Management: How can i optimise my commercial strate...
Global Pricing and Tender Management: How can i optimise my commercial strate...Global Pricing and Tender Management: How can i optimise my commercial strate...
Global Pricing and Tender Management: How can i optimise my commercial strate...
 
Pharma Pricing & Market Access
Pharma Pricing & Market AccessPharma Pricing & Market Access
Pharma Pricing & Market Access
 

Using Mobile Phones to Collect End Line Evaluation Data for the Essential Drug Logistics System Pilot in Zambia: Dr Arturo Sanabria/Wendy Nicodemus

  • 1. Using Mobile Phones to Collect End Line Evaluation Data for the Essential Drug Logistics System Pilot in Zambia Dr. Arturo Sanabria Wendy Nicodemus
  • 2. Background • Zambian MoH has invested substantial funds in the public sector drug system – Health centres continue to have difficulty accessing these drugs and medical supplies • MoH and key partners proposed a pilot project to improve drug availability at health centres and hospitals across Zambia
  • 3. Goal of the Pilot Test two different logistics system models to select one (or a combination/variation) that can be rolled out nationally, in order to significantly improve the availability of key essential drugs at service delivery sites
  • 4. The Pilot Models System A System B • District Store • District Store remains as converted to cross- stockholding point docking point VS • Districts submit • Districts submit consolidated orders individual orders for every month and each facility and receive consolidated receive goods packed deliveries from MSL for individual facilities
  • 5. 16 Pilot Districts and 8 Control Districts
  • 6. Essential Drug Logistics System Pilot Evaluation • Facilities in pilot and control districts evaluated at baseline and endline to determine impact • Endline evaluation used mobile phones to collect data at 259 health facilities and district health offices in 16 pilot districts and 8 control districts
  • 7. Methodology • Mobile phones used to collect data, including: – Stock status at facility – Storage conditions at facility – Order fulfillment rate – Impact of training in logistics management • Data from mobile phones sent to EpiSurveyor (www.episurveyor.org) for aggregation • Data shared via the website to all partners involved
  • 8.
  • 9. Lessons Learned • Final results presented 5 days after last facility visit – Previous evaluations took a month to present final results • Mobile phone use requires detail-oriented data management reviewing the online database regularly – Requires continuous review of data – Need IT support to address any bugs with the mobile phones
  • 10. Lessons Learned • Preliminary data analysis ongoing throughout evaluation • Technology works best when mobile phone network is strong and can be transmitted to server immediately – When no mobile network, data sent to server at a later point negating benefit of real- time data review
  • 11. Conclusions • Mobile phone technology for data collection is appropriate when conducting health facility level surveys. • The technology is user-friendly and easy to train. • This technology is not necessarily the appropriate tool for routine site-level data collection as it requires a reliable mobile network.